Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, holds 243.02K shares in Nektar Therapeutics (Ticker: NKTR). Most recently, Jonathan Zalevsky Sold $7,785 shares of Nektar Therapeutics on Nov 20, 2024 for an estimated value of 7.86K.
What is the percentage of profitable transactions made by Jonathan Zalevsky?
The percentage of profitable transactions made by Jonathan Zalevsky is 38%.
What is the average return per transaction made by Jonathan Zalevsky?
The average return per transaction made by Jonathan Zalevsky is -41.40%.
What stocks does Jonathan Zalevsky hold?
Jonathan Zalevsky holds: NKTR stocks.
What was Jonathan Zalevsky’s latest transaction?
Jonathan Zalevsky latest transaction was an Informative Sell of $7.86K.
What was Jonathan Zalevsky's most profitable transaction?
Jonathan Zalevsky’s most profitable transaction was an Informative Sell of NKTR stock on November 18, 2022. The return on the trade was 86.20%.
What is Jonathan Zalevsky's role in Nektar Therapeutics?
Jonathan Zalevsky's role in Nektar Therapeutics is Chief R&D Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.